Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 04:30PM GMT
Release Date Price: $114.97 (-3.88%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

All right. Great, everybody. We're going to get going with the next session. I'm Matthew Harrison, one of the Biotech Analysts here at Morgan Stanley. Very pleased to have Doug Ingram, the CEO of Sarepta with me for the next session. Just briefly before we get started, I have to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. Doug has promised that he is going to read the FDA communication for us. That will entail the entire session. No, sorry.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So Doug, I mean, I guess, look, maybe the first place to start is you've obviously had a bunch of back and forth. I think you've been public about sort of the commentary. I guess, maybe just walk us through what the rest of the fall looks like leading up

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot